

Date and Time: 25th October 2013 10:00 – 16:00

Minutes: Confirmed

**Multiple Sclerosis Guideline
Development Group Meeting 10**

Place: Boardroom, National Clinical Guideline Centre, 180 Great Portland Street,
London, W1W 5QZ

Present: GDG

1. Paul Cooper	PC
2. Jeremy Chataway	JC
3. Wendy Hendrie	WH
4. Susan Hourihan	SH
5. Noreen Barker	NB
6. Richard Warner	RW
7. Aleks de Gromoboy	ADG
8. Emma Rowe	ER
9. Pamela Bostock	PBo
10. Sarah Gillanders (co-optee)	SG

NCGC Technical team

11. Sharon Swain	SS
12. Mark Perry	MP
13. Amy Kelsey	AK
14. Sophia Winterbourne	SW
15. Norma O'Flynn	NOF

NICE:

1. Caroline Keir	CK
------------------	----

Apologies

1. David Kernick	DK
2. Ann Hodgson	AH
3. Krishna Chinthapalli	KC
4. Peter Brex	PB

Notes

1. The Chair welcomed the group to the Multiple Sclerosis Guideline Development Group (GDG) meeting 10. Apologies were received from David Kernick, Ann Hodgson, Krishna Chinthapalli and Peter Brex. The Chair introduced Sarah Gillanders, an MS Specialist Clinical Neuropsychologist, to the GDG.
2. The Chair asked the GDG to declare any personal specific, personal non-specific, non-personal specific or non-personal non-specific interests:

SG declared the following personal pecuniary interest: she is speaking at the MS Trust conference (conference fees, travel and accommodation funded by the MS Trust).

PC declared the following personal pecuniary interest: he is attending a workshop organised by UCL, travel and accommodation funded by unrestricted grant from UCB Pharma. He also declared the following non-personal pecuniary interest: a research fund on which he is a trustee recently received a small grant of £350 from UCB to support a training course.

There were no other new declarations of interest.

3. An update was then given to the GDG on progress since the last meeting.
4. The Chair introduced Sarah Gillanders who gave a presentation to the GDG that outlined how she carried out a neuropsychological assessment and cognitive rehabilitation with people with MS. The Chair thanked SG for her presentation.
5. The Chair introduced Sharon Swain, NCGC Senior Research Fellow, who presented the clinical evidence of non-pharmacological management of memory and cognitive problems with neuropsychological rehabilitation. The GDG discussed the evidence. The Chair thanked SS for her presentation.
6. The Chair introduced Sophia Winterbourne, NCGC Health Economist, who presented the economic evidence of non-pharmacological management of memory and cognitive problems with neuropsychological rehabilitation. The GDG discussed the evidence. The Chair thanked SW for her presentation.
7. The Chair introduced Mark Perry, NCGC Research Fellow, who presented the clinical evidence of non-pharmacological treatment of ataxia and tremor with neurorehabilitation. The GDG discussed the evidence. The Chair thanked MP for his presentation.
8. The Chair introduced Sophia Winterbourne, NCGC Health Economist, who presented the economic evidence of non-pharmacological treatment of ataxia and tremor with neurorehabilitation. The GDG discussed the evidence. The Chair thanked SW for her presentation.
9. The Chair introduced Mark Perry, NCGC Research Fellow, who presented the clinical evidence of pharmacological management of emotionalism with antidepressants. The GDG discussed the evidence. The Chair thanked MP for his presentation.
10. The Chair introduced Sophia Winterbourne, NCGC Health Economist, who presented the economic evidence of pharmacological management of emotionalism with antidepressants. The GDG discussed the evidence. The Chair thanked SW for her presentation.
11. SW then presented an update of the health economic review for the pharmacological treatment of fatigue. The GDG discussed the update. The Chair thanked SW for her presentation.

Notes

- 12 The Chair introduced Norma O'Flynn, NCGC Clinical Director, who presented the research recommendations process to the GDG. The Chair thanked NOF for her presentation.
- 13 There was no AOB. The Chair closed the meeting and thanked everyone for attending

Date, time and venue of the next meeting

Thursday 5th December 2013, 10:00 – 13:00, Boardroom, National Clinical Guideline Centre, 180 Great Portland Street, London, W1W 5QZ